ADMA

ADMA Biologics, Inc. - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. ADMA Biologics, Inc. is a commercial biopharmaceutical company focused on manufacturing and marketing specialty biologics, primarily immune globulins. The company operates two main segments: ADMA BioManufacturing (manufacturing and commercialization of ASCENIV, BIVIGAM, and Nabi-HB) and ADMA BioCenters (source plasma collection). As of March 31, 2026, the company operated seven FDA-licensed plasma collection centers following the divestiture of three centers earlier in the quarter.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Mix Shift: While total revenue remained flat, the product mix shifted significantly. ASCENIV revenue increased 27.7% to $97.5 million, driven by market acceptance. Conversely, BIVIGAM revenue declined 54.0% to $15.4 million due to competitive pricing pressures and lower volume in the standard IVIG market.
• Margin Expansion: Gross margin improved to 70.5% from 53.2% year-over-year. This was driven by a favorable product mix (higher ASCENIV sales) and the implementation of an FDA-approved yield enhancement manufacturing process.
• Asset Divestiture: The company completed the sale of three plasma collection centers (Maryville, Knoxville, and Laurel) for an aggregate purchase price of $12.0 million, recognizing a gain of $8.0 million in Q1 2026.
• Debt and Liquidity: The company borrowed $125.0 million under its JPM Revolving Credit Facility in March 2026 to fund an Accelerated Share Repurchase (ASR) agreement. Total debt increased significantly from $72.1 million to $196.9 million, though cash balances also rose to $138.2 million.
• Share Repurchases: The company repurchased approximately 6.75 million shares for a total cost of $111.1 million, including 6.42 million shares received under the ASR agreement.

Guidance, Outlook, and Risks

• Yield Enhancement: Management expects the yield enhancement process (approved in April 2025) to drive meaningful revenue and earnings accretion throughout 2026 and beyond, with production yields increasing by 20% or more.
• Regulatory Milestone: In May 2026 (subsequent to the period end), the FDA approved an expansion of the ASCENIV label to include the pediatric setting for patients two years of age and older.
• Competitive Landscape: The company faces aggressive pricing tactics from new FDA-approved IVIG products entering the market, which has led to increased inventory in the distribution network and impacted BIVIGAM sales.
• Liquidity Outlook: Management anticipates that current cash, cash equivalents, and projected operating cash flows will be sufficient to fund operations through the first quarter of 2027.
• Risks: Key risks include reliance on third-party suppliers for high-titer RSV plasma, potential supply chain disruptions, and the impact of competitive pricing on market share. The company also faces risks related to the realization of deferred tax assets and compliance with debt covenants.

Investor Verification Checklist

• ASCENIV Growth Trajectory: Verify if the 27.7% growth rate in ASCENIV sales is sustainable given the new pediatric label expansion and competitive pressures.
• BIVIGAM Decline: Assess the long-term impact of the 54% revenue decline in BIVIGAM and whether the yield enhancement process can offset volume losses.
• Debt Utilization: Confirm the company's ability to service the increased debt load ($196.9 million) while maintaining the required leverage ratios (max 2.50:1) under the JPM Credit Agreement.
• Plasma Supply Security: Review the terms of the new long-term plasma supply agreements entered into following the divestiture of three centers to ensure adequate RSV plasma supply for ASCENIV production.
• Non-GAAP Reconciliations: Examine the reconciliation of Adjusted EBITDA ($59.7 million) and Adjusted Net Income ($40.7 million) to understand the impact of one-time items like the gain on sale of plasma centers.